Trial Profile

A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jan 2023 Results (n=13) reporting safety and antiviral activity from phase 1b published in the Journal of Viral Hepatitis
26 Jun 2021 Results (n=25) assessing safety labs, pharmacokinetics, and antiviral activity of ATI-2173 in treatment-naive subjects with chronic HBV-infection, presented at The International Liver Congress 2021.
26 Jun 2021 Results (n=17) assessing safety, tolerability, pharmacokinetics, and antiviral activity of ATI-2173 in a phase 1b clinical trial, presented at The International Liver Congress 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com